Takeda, Santhera Extend Partnership On Idebenone To Duchenne Muscular Dystrophy
This article was originally published in The Pink Sheet Daily
Executive Summary
Takeda and the Swiss specialty pharma Santhera Pharmaceuticals are extending an existing collaboration on SNT-MC17 (idebenone) for the neuromuscular disease Friedreich's Ataxia to include a second indication for Duchenne muscular dystrophy, the firms announced Aug. 2